Get started
Author

Anca Chelariu-Raicu

Observed names: A Chelariu-Raicu, A. Chelariu-Raicu, Anca Chelariu, Anca Chelariu Raicu, Anca Chelariu- Raicu, Anca Chelariu-Raiciu, Chelariu-Raicu Anca
Observed institutions: The University of Texas MD Anderson Cancer Center, German Cancer Research Center, George Washington University, University of Münster, Richmond University Medical Center, LMU Klinikum, Klinik für Frauenheilkunde, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe, University Hospital Münster, München Klinik, München Klinik Harlaching, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Deutsches Konsortium für Translationale Krebsforschung, Rice University, Ludwig-Maximilians-Universität München
ORCID: 0000-0003-2944-9488
Observed ORCID: 0000-0003-2944-9488
OpenAlex ID: A5001850756
Targeting KRAS in Cancer: Promising Therapeutic Strategies
2021 · Lisa Maria Mustachio, Anca Chelariu-Raicu, et al. · Cancers · 89
PDF
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
2021 · Shannon N. Westin, Marilyne Labrie, et al. · Clinical Cancer Research · 79
PDF
Immunotherapy in endometrial cancer
2023 · Haider Mahdi, Anca Chelariu-Raicu, et al. · International Journal of Gynecological Cancer · 67
Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
2020 · Mingjun Zheng, Heather Mullikin, et al. · International Journal of Molecular Sciences · 44
PDF
Abstract 122: Targeting forward and reverse EphB4/EFNB2 signaling by a peptide with dual functions
2020 · Chiyi Xiong, Yunfei Wen, et al. · Cancer Research · 44
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
2023 · Christopher J. LaFargue, Paola Amero, et al. · Nature Communications · 40
PDF
Integrating antibody drug conjugates in the management of gynecologic cancers
2023 · Anca Chelariu-Raicu, Sven Mahner, et al. · International Journal of Gynecological Cancer · 28
PDF
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective
2021 · Marie Forster, Rachel Wuerstlein, et al. · The Breast · 26
PDF
Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer
2021 · Mingjun Zheng, Junyu Long, et al. · Cancers · 25
PDF
Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype
2016 · Anca Chelariu-Raicu, Cornelia Wilke, et al. · Fertility and Sterility · 21
PDF
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
2020 · Anca Chelariu-Raicu, Alpa Nick, et al. · Gynecologic Oncology · 20
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
2022 · Susann Badmann, Doris Mayr, et al. · Scientific Reports · 18
PDF
The Cell Surface Heparan Sulfate Proteoglycan Syndecan-3 Promotes Ovarian Cancer Pathogenesis
2022 · Lara Hillemeyer, Nancy Adriana Espinoza-Sanchez, et al. · International Journal of Molecular Sciences · 17
PDF
Prostaglandin E2 receptor 3 promotes M1 macrophages polarization in unexplained recurrent pregnancy loss
2022 · Yao Ye, Lin Peng, et al. · Biology of Reproduction · 17
Expression of the Carbohydrate Lewis Antigen, Sialyl Lewis A, Sialyl Lewis X, Lewis X, and Lewis Y in the Placental Villi of Patients With Unexplained Miscarriages
2021 · Zhi Ma, Huixia Yang, et al. · Frontiers in Immunology · 17
PDF
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
2019 · Anca Chelariu-Raicu, Robert L Coleman, et al. · PubMed · 17
Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine
2024 · Jibran Ahmed, Carlos Torrado, et al. · JCO Precision Oncology · 16
The Impact of the COVID-19 Pandemic on Sexual Health in Cis Women Living in Germany
2022 · Falk Batz, Eva Lermer, et al. · The Journal of Sexual Medicine · 16
Actin Beta-Like 2 as a New Mediator of Proliferation and Migration in Epithelial Ovarian Cancer
2021 · Nicole Elisabeth Topalov, Doris Mayr, et al. · Frontiers in Oncology · 16
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer
2020 · Mark Seungwook Kim, Shaolin Ma, et al. · Molecular Cancer Therapeutics · 16
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions
2020 · Chiyi Xiong, Yunfei Wen, et al. · Scientific Reports · 15
PDF
The Platelet-Activating Factor Receptor’s Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine
2021 · Eileen Deuster, Ivi Hysenaj, et al. · Cells · 14
PDF
Prostaglandin E2 Receptor 4 (EP4) Affects Trophoblast Functions via Activating the cAMP-PKA-pCREB Signaling Pathway at the Maternal-Fetal Interface in Unexplained Recurrent Miscarriage
2021 · Lin Peng, Anca Chelariu-Raicu, et al. · International Journal of Molecular Sciences · 13
PDF
Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer
2021 · Tilman L. R. Vogelsang, Aurelia Vattai, et al. · International Journal of Molecular Sciences · 13
PDF
Fertility preservation in rare ovarian tumors
2021 · Anca Chelariu-Raicu, Lauren P Cobb, et al. · International Journal of Gynecological Cancer · 13
Works count: 153
Citation count: 857
H-index: 16
I10-index: 31
Year
Topic
Type